Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial.
Huabin HuJian-Wei ZhangYunfeng LiXiaozhong WangZi-Qiang WangHui WangLiang KangPing LiuPing LanXiao-Jian WuYunhuan ZhenHaiping PeiZhongcheng HuangHao ZhangWenbin ChenYongming ZengJiajun LaiHongbo WeiXuefeng HuangJiansi ChenJigui ChenKaixiong TaoQingwen XuXiang PengJunlin LiangGuanfu CaiChengcheng LiuZhijie DingMing HuWeiyuan ZhangBo TangChuyuan HongJie CaoZonghai HuangWuteng CaoFangqian LiXinhua WangChao WangYan HuangYandong ZhaoYue CaiJiayu LingXiaoyu XieZehua WuLishuo ShiLi LingHao LiuJianping WangMeijin HuangYan-Hong Dengnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
NAC with mFOLFOX6 or CAPOX did not show a significant DFS benefit. However, this neoadjuvant approach was safe, resulted in substantial pathologic downstaging, and appears to be a viable therapeutic option for locally advanced colon cancer.
Keyphrases
- phase iii
- neoadjuvant chemotherapy
- locally advanced
- open label
- phase ii study
- lymph node
- rectal cancer
- clinical trial
- double blind
- placebo controlled
- phase ii
- squamous cell carcinoma
- minimally invasive
- sentinel lymph node
- radiation therapy
- coronary artery bypass
- transcription factor
- high resolution
- high speed
- study protocol
- surgical site infection
- metastatic colorectal cancer
- early stage
- percutaneous coronary intervention